RxDoctor Payments Data

Susan Grumbach

Family · Camden, SCNPI 1831465624

Payments from drug & device makers

$7,650in general payments, 2019–2025

Across 443 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$922
  • Lilly USA, LLC$635
  • Pfizer$510
  • Amgen$505
  • GSK$423
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$7,57099%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,650 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide41$52,763
EliquisApixaban74$50,941
RybelsusSemaglutide28$38,477
JardianceEmpagliflozin29$34,919
FarxigaDapagliflozin Propanediol39$30,169
OzempicSemaglutide28$26,811
Janumet XrSitagliptin Phos/Metformin Hcl34$25,085
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$21,096
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$8,607
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$7,779
XyostedTestosterone Enanthate11$6,675
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$5,515
MultaqDronedarone Hcl12$4,542
Levothyroxine Sodium279$3,146
Ezetimibe93$3,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$922$65,28756 claims
Lilly USA, LLCMounjaro$635$52,76341 claims
PfizerEliquis$510$50,94174 claims
AstraZenecaFarxiga, Breztri Aerosphere$397$38,77654 claims
Boehringer IngelheimJardiance$215$34,91929 claims
MerckJanumet Xr$116$25,08534 claims
GSKTrelegy Ellipta$423$21,09621 claims
Antares Pharma, Inc.Xyosted$99$6,67511 claims
Sanofi-aventis U.S. LLCMultaq$143$4,54212 claims
AbbVieSynthroid$1,081$96415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Camden

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →